Back to Search Start Over

Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia

Authors :
Aarif M. N. Batcha
Tobias Herold
Stefan K. Bohlander
Dennis Görlich
Bianka Ksienzyk
Wolfgang E. Berdel
Jan Braess
Wolfgang Hiddemann
Alexander Graf
Ulrich Mansmann
Stephanie Schneider
Maria Cristina Sauerland
Bernhard J. Woermann
Karsten Spiekermann
Stefan Krebs
Hanna Janke
Nikola P. Konstandin
Vindi Jurinovic
Julia Philippou-Massier
Klaus H. Metzeler
Stefan Canzar
Maja Rothenberg-Thurley
Stefanos A. Bamopoulos
Helmut Blum
Source :
Leukemia 34, 2621–2634 (2020)
Publication Year :
2020
Publisher :
Springer Science and Business Media LLC, 2020.

Abstract

Previous studies have demonstrated that splicing factor mutations are recurrent events in hematopoietic malignancies. Their clinical characteristics and aberrant splicing patterns have been explored in myelodysplasia, however, their functional consequences in acute myeloid leukaemia are largely unknown. The aim of this study was the comprehensive clinical and functional analysis of mutations in the three most commonly afflicted splicing factor genes: SRSF2 , U2AF1 and SF3B1 . To this end, we examined the prognostic role of splicing factor mutations in two large independent cohorts, encompassing a total of 2678 acute myeloid leukaemia patients treated with intensive chemotherapy. The clinical analysis was complemented by RNA-sequencing of 246 patients to identify targets of splicing dysregulation. Results were validated in an additional RNA-sequencing dataset of 177 patients. Patients with splicing factor mutations show inferior relapse-free and overall survival, however, these mutations do not represent independent prognostic markers. Differential isoform expression analysis revealed a characteristic expression profile for each splicing factor mutation with a strong dysregulation of several isoforms. Furthermore, by establishing a custom differential splice junction usage pipeline we accurately detected aberrant splicing in splicing factor mutated samples. Mutated samples were characterized by predominantly decreased splice junction utilization of a large number of genes. A large proportion of differentially used spliced junctions were novel. Targets of splicing dysregulation included several genes with a known role in acute myeloid leukaemia. In SRSF2 (P95H) mutants we further explored the possibility of a cascading effect through the dysregulation of the splicing pathway. Taken together, our findings suggest that splicing factor mutations does not represent independent prognostic markers. However, they do have genome-wide consequences on gene splicing leading to dysregulated isoform expression of several genes.

Details

ISSN :
14765551 and 08876924
Volume :
34
Database :
OpenAIRE
Journal :
Leukemia
Accession number :
edsair.doi.dedup.....c4b31530b59e4faf05a198628ca8ad1a